You are here

gene therapy

Sarepta Invests $30 Million in Gene Therapy Company

Sarepta Invests $30 Million in Gene Therapy Company

CP Wire

Lacerta Therapeutics

Sarepta Therapeutics

Flag link:

RegenxBio rally fades fast after biotech reports setbacks, hospitalization in gene therapy study

RegenxBio rally fades fast after biotech reports setbacks, hospitalization in gene therapy study

Endpoints

clinical trials

Flag link:

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer

Forbes

Flag link:

Boehringer Ingelheim lands option on cystic fibrosis gene therapy

Boehringer Ingelheim lands option on cystic fibrosis gene therapy

Fierce Biotech

Boehringer Ingelheim

cystic fibrosis

Oxford BioMedica

Flag link:

Bluebird’s first gene therapy gets European fast track

Bluebird’s first gene therapy gets European fast track

PM Live

Flag link:

FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results

FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock

Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock

Endpoints

PTC Therapeutics

Flag link:

Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

Zacks.com

fidanacogene elaparvovec

Flag link:

FDA Releases Six New Draft Guidances on Gene Therapy

FDA Releases Six New Draft Guidances on Gene Therapy

CP Wire

Flag link:

FDA Releases Six New Draft Guidances on Gene Therapy

Flag link:

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Focused on rebuilding the pipeline, Axovant’s new crew assembles another preclinical gene therapy deal

Endpoints

Axovant Sciences

Flag link:

Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far

Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far

Motley Fool

beta thalassemia

Flag link:

3 Best Gene Therapy Stocks of 2018 (So Far)

3 Best Gene Therapy Stocks of 2018 (So Far)

Motley Fool

Sarepta Therapeutics

Solid Biosciences

Flag link:

The Human Genome Project: At the Root of a Healthcare Revolution

The Human Genome Project: At the Root of a Healthcare Revolution

Yahoo/Motley Fool

Human Genome Project

drug development

Flag link:

Demand For Gene Therapies To Prompt Surge In Pharma M&A

Demand For Gene Therapies To Prompt Surge In Pharma M&A

Forbes

Sangamo Therapeutics

Flag link:

Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease

Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease

CP Wire

sickle cell disease

Flag link:

Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder

Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder

CP Wire

beta thalassemia

sickle cell disease

Flag link:

Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200

Novartis' brand-new gene therapy player AveXis will build $55M plant, hire 200

Fierce Pharma

drug manufacturing

Flag link:

Is biopharma’s first $1.5M therapy now in Phase III?

Is biopharma’s first $1.5M therapy now in Phase III?

Endpoints

Spark Therapeutics

Flag link:

First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy

First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy

CP Wire

clinical trials

spinal muscular atrophy

Flag link:

Pages